J&J Prostate Cancer Drug Shows Major Benefits

Johnson & Johnson's prostate cancer drug, Erleada, has demonstrated significant benefits when used alongside hormone-blocking therapy. Data from a late-stage clinical trial, followed for over five years, revealed that this combination treatment substantially improved cancer elimination following surgery.

Patients receiving the combined therapy were nine times more likely to have little to no detectable cancer after prostate surgery compared to those on hormone therapy alone. Johnson & Johnson reported that this approach also decreased the risk of cancer progression or death by 20%.

In a separate evaluation of a longer treatment regimen, encompassing a full year of Erleada and hormone therapy before and after surgery, patients experienced even greater advantages. On average, these men delayed the need for additional treatments for over six years, nearly double the time of those receiving only hormone therapy.

This extended Erleada treatment also led to a 29% reduction in the risk of cancer recurrence and death. These findings, presented at the American Society of Clinical Oncology meeting, may influence future treatment protocols for high-risk localized or locally advanced prostate cancer.